Pre Exposure Prophylaxis News and Research

RSS

NIH awards $11.3 million grant to renew the Einstein-Rockefeller-CUNY Center for AIDS Research

The National Institutes of Health has awarded Albert Einstein College of Medicine a five-year, $11.3 million grant to renew the Einstein-Rockefeller-CUNY Center for AIDS Research and expand its efforts to prevent, treat and cure HIV infection, and thereby reduce the burden of HIV, locally, nationally, and internationally.

3 May 2022

Advancements in HIV science

As far as viruses go, human immunodeficiency virus (HIV) is quite simple. About 100,000 times smaller than a red blood cell, the virus expresses just a dozen proteins, yet it can establish a lifelong infection that, if left untreated, causes acquired immunodeficiency syndrome (AIDS) and death.

20 Apr 2022

Evaluating serological responses to repeated COVID-19 vaccination in kidney transplant recipients

Researchers analyzed whether repeated vaccinations against COVID-19 increase serological response in non-responding kidney transplant recipients.

29 Mar 2022

Neutralization of BA.1 and BA.2 Omicron variants with monoclonal antibodies

A new research paper published as an early release manuscript in the Nature Medicine journal compares the sensitivity of this strain as well as the earlier Delta and the newer BA.2 to therapeutic mAbs.

27 Mar 2022

Evusheld™ found to poorly neutralize Omicron in kidney transplant patients

Researchers evaluated the neutralizing antibody titers and anti-receptor-binding domain immunoglobulin G titers in sera of kidney transplant recipients who were vaccinated against COVID-19 and treated with 300 mg dosage of Evusheld™

25 Mar 2022

MHRA authorizes new medicine for COVID-19 prevention

A new medicine, Evusheld (tixagevimab/cilgavimab), has today been authorised for COVID-19 prevention by the Medicines and Healthcare products Regulatory Agency (MHRA) after meeting the UK regulatory standards of safety, quality and effectiveness.

17 Mar 2022

Researchers find unprecedented rise in HIV incidence rate among people who inject drugs in Tijuana

At the February 11, 2022 opening of the Conference on Retroviruses and Opportunistic Infection, researchers at University of California San Diego School of Medicine presented data that suggests a new HIV outbreak in Tijuana, Mexico, driven in part by "drug tourism" unabated by the closure of the international border due to the COVID-19 pandemic.

12 Feb 2022

New research confirms the safety of mRNA COVID-19 vaccines for people with cancer

New research in the February 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network confirms that mRNA vaccine for COVID-19 are just as safe for people with cancer as they are for cancer-free individuals.

10 Feb 2022

Nurses play a critical role in reducing health misinformation

On July 15, 2021, the U.S. Surgeon General issued an urgent plea for all Americans to take part in slowing a serious threat to public health. He wasn't talking about the COVID-19 pandemic but rather the harmful effects on personal and public health caused by the infodemic – the creation and spread of an excessive amount of unreliable and false health information.

4 Feb 2022

One in five young sexual minority men and transgender women may engage in transactional sex

About a fifth of young sexual minority males and transgender females are estimated to be engaging in transactional, or survival sex, according to results of a new survey study by Johns Hopkins Medicine researchers.

25 Jan 2022

Study reveals how state laws affect access to HIV pre-exposure prophylaxis

State laws in the US that require medical doctors (MDs) to determine which medications a nurse practitioner (NP) or physician assistant (PA) can prescribe, and under what conditions, may limit the number of patients who use HIV pre-exposure prophylaxis (PrEP), reports a study in The Journal of the Association of Nurses in AIDS Care.

22 Jan 2022

FDA approval of long-acting injectable drug marks a vital expansion of HIV prevention options

Yesterday the U.S. Food and Drug Administration announced its first approval of a long-acting HIV prevention medication. Developed by ViiV Healthcare, the medicine is long-acting cabotegravir injected once every two months.

21 Dec 2021

New analysis highlights the global prevalence of HIV among transgender people

A new analysis highlights the prevalence of HIV among transgender individuals worldwide, and shows the need for continued prevention efforts for this population.

1 Dec 2021

World AIDS Day: New Vital Signs report highlights persistent disparities in HIV prevention and care

Despite overall progress in reducing new infections among gay and bisexual men, the HIV epidemic continued and was more severe among Black or African American (hereafter referred to as Black) and Hispanic/Latino gay and bisexual men in the decade leading up to the federal Ending the HIV Epidemic in the U.S. (EHE) initiative, which the U.S. Department of Health and Human Services launched in 2019.

1 Dec 2021

Scientists now close to eliminating mother-baby HIV transmission, says leading researcher

Quarraisha Abdool Karim has spent the past three decades studying HIV and AIDS. She has become one of the world's leading epidemiologists and made major contributions to the global understanding of how HIV affects young women.

24 Nov 2021

RA patients taking glucocorticoids or B-cell therapies may have worse COVID-19 vaccine response

New research presented this week at ACR Convergence, the American College of Rheumatology's annual meeting, shows that people with chronic inflammatory diseases, such as rheumatoid arthritis (RA), who take immunosuppressive therapy appear to have an impaired immunity response to SARS-CoV-2, the coronavirus that causes COVID-19, vaccines. Patients currently on glucocorticoids or B-cell depleting therapy appear to have an even more severely impeded vaccine response.

2 Nov 2021

Analysis shows dramatic fall in the number of people living with undiagnosed HIV in England

England is on track to have diagnosed 95% of people living with HIV by 2025, putting it in a strong position to eliminate HIV transmission by 2030, say researchers at the MRC Biostatistics Unit, University of Cambridge, and Public Health England (PHE).

24 Sep 2021

Johns Hopkins Medicine mathematical model to play major role in ending HIV nationwide

A new Johns Hopkins Medicine mathematical model to predict how the human immunodeficiency virus (HIV) spreads in urban areas will play a major role in a federal initiative aiming to reduce the incidence of HIV infections in the United States by 90% between 2020 and 2030.

24 Sep 2021

Investigational vaccine does not provide sufficient protection against HIV infection

An investigational HIV vaccine tested in the "Imbokodo" clinical trial conducted in sub-Saharan Africa posed no safety concerns but did not provide sufficient protection against HIV infection, according to a primary analysis of the study data. The Phase 2b proof-of-concept study, which began in November 2017, enrolled 2,637 women ages 18 to 35 years from five countries.

31 Aug 2021

Certain high priority groups more likely to stop taking HIV prevention treatment, study finds

A large, detailed look at patients taking HIV-prevention drug therapy finds strong adherence soon after patients get the prescription, but less consistent use thereafter, particularly among groups considered high priority for receiving the medication.

27 Aug 2021